CD30 CAR T-cells Post AutoHSCT for Poor-risk Hodgkin Lymphoma (NCT06617286)
MAC-CAR: A Phase 1B/II Trial of Myeloablative Conditioning and Autologous Stem Cell Transplantation Followed by Autologous CD30+ CAR T Cells in Children, Adolescents and Young Adults With Poor-Risk Classical Hodgkin Lymphoma (cHL)
🩺 Plain-English Summary (8th-Grade Level)
Patients with poor risk classical Hodgkin Lymphoma (cHL) will undergo myeloablative chemotherapy (MAC) with autologous stem cell transplantation (AutoHSCT) and subsequently receive autologous CD30+ CAR T-cells.
Who can join: Review the eligibility criteria below.
Location: New York Medical College — Valhalla, New York
Age range: 6 Years to 29 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (1 Sites)
- New York Medical College — Valhalla, New York
📞 Contact the Study Coordinator
Phone: (914) 594-2150
Email: mitchell_cairo@nymc.edu
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Classical Hodgkin Lymphoma
- Fitness-adapted, Pembrolizumab-based Therapy for Untreated Classical Hodgkin Lymphoma Patients 60 Years of Age and Above — New Brunswick, New Jersey
- Itacitinib + Everolimus in Hodgkin Lymphoma — Philadelphia, Pennsylvania
- Ibrutinib and Nivolumab in Treating Patients With Relapsed or Refractory Classical Hodgkin Lymphoma — Atlanta, Georgia
- Autologous CD30.CAR-T in Combination With Nivolumab in cHL Patients After Failure of Frontline Therapy — Duarte, California
- Study of Pembrolizumab With Bendamustine in Hodgkin Lymphoma — Toronto, Ontario
Explore by condition: All Classical Hodgkin Lymphoma clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.